We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Abeona Therapeutics Inc (ABEO) USD0.01

Sell:$6.87 Buy:$6.91 Change: $0.03 (0.43%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$6.87
Buy:$6.91
Change: $0.03 (0.43%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$6.87
Buy:$6.91
Change: $0.03 (0.43%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing cell and gene therapies for life-threatening diseases. The Company’s lead clinical program is EB-101, an autologous, engineered cell therapy in development for recessive dystrophic epidermolysis bullosa (RDEB). Its development portfolio also features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with unmet medical needs. The Company’s next generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its fully integrated cell and gene therapy Good Manufacturing Practice (cGMP) manufacturing facility produced EB-101 for the pivotal Phase III VIITAL study and is capable of clinical and potential commercial production of AAV-based gene therapies. EB-101 is an autologous, engineered cell therapy in which a functioning COL7A1 gene is inserted into a patient’s own skin cells (keratinocytes) using a retrovirus.

Contact details

Address:
6555 CARNEGIE AVE, 4TH FLOOR
CLEVELAND
44103
United States
Telephone:
+1 (646) 8134701
Website:
https://abeonatherapeutics.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ABEO
ISIN:
US00289Y2063
Market cap:
$182.08 million
Shares in issue:
24.77 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Michael Amoroso
    Chairman of the Board
  • Vishwas Seshadri
    President, Chief Executive Officer, Director
  • Joseph Vazzano
    Chief Financial Officer
  • Brendan O Malley
    General Counsel
  • Madhav Vasanthavada
    Chief Commercial Officer, Head of Business Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.